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REST regulatory circuit controls distinct oncogenic properties of glioblastoma
stem cells through specific microRNAs
Anantha Marisetty, M.S.
Advisory Professor: Sadhan Majumder, Ph.D
Glioblastoma Multiforme (GBM) is the most common and aggressive primary malignant
brain tumor in adults. With an average survival of only 12-16 months the prognosis for
GBM patients remains dismal, with less than 5% of patients surviving 5 years. New
mechanism-based approaches are necessary for the management of patients with
GBM. Many GBM tumors are believed to be caused by self-renewing, glioblastomaderived stem-like cells (GSCs). These GSCs are resistant to chemo- and radiation
therapies, and are believed to be responsible for tumor recurrence. In a recent paper
from our lab we have shown that REST, RE1-silencing transcription factor, regulates
oncogenic properties such as proliferation, invasion, and apoptosis in GSCs. However,
the mechanism by which REST regulates oncogenic properties of GSCs is not clearly
understood. Thus, the overall aim of this project is to delineate the mechanism by
which REST mediates oncogenic properties of GSCs. Using genome-wide expression
analysis followed by biochemical validations, we show that REST targets two
microRNAs, miR-124 and miR-203 in High REST GSCs (HR-GSCs). Independent
studies were carried out to determine the role of these microRNAs in HR-GSC derived
brain tumors. Gain of function of either miR-124 or miR-203 in HR-GSCs leads to
increased survival when tumor cells are transplanted into mice.

Importantly, the

increased survival of tumor-bearing mice caused by knockdown of Rest in HR-GSCs
5

can be reversed by double knockdown of Rest and miR-124 or miR-203, indicating that
the REST-miR-124/miR-203 axis controls tumorigenesis. We further show that the
REST-miR-124 axis regulates proliferation, invasion and apoptosis of GSCs both in
vitro and in vivo, while the REST-miR-203 axis specifically regulates invasion and not
proliferation or apoptosis. Our results indicate that invasion is a major hallmark of HRGSC tumors and that the REST-miR-124/203 axis is critical in this process. These
results also suggest that the REST-miR-124/203 axis could potentially be targeted in
therapeutic approaches to block invasion in REST-stratified GBM tumors.
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Chapter 1: Introduction
1.1 Overview
Glioblastoma (GBM; Glioblastoma Multiforme) is the most common and aggressive
form of adult brain tumors with a mean survival of 12-16 months (1-5). The current
therapies for GBM patients involve surgical resection followed by radiation and
chemotherapy or a combination of both (2, 3, 6, 7). Many GBM tumors are believed to
be caused by self-renewing, glioblastoma-derived stem-like cells (GSCs) that are highly
proliferative, invasive and resistant to chemo- and radiation therapies, and are believed
to be responsible for tumor recurrence (8-16). Recent studies from three different
groups (17-19), including ours, have shown that RE1 silencing transcriptional factor
(REST) regulates self-renewal and oncogenic properties like proliferation, apoptosis
and invasion in a class of GSCs. However, the mechanistic understanding of the REST
driven self-renewal and oncogenesis needs further elucidation. The purpose of this
study was to determine the mechanism by which REST regulates these oncogenic
properties (proliferation, apoptosis and invasion) of GSCs and this will produce new
mechanisms that can potentially be used for novel mechanism-based targeted therapy
in GBM.

1.2 Glioblastoma (GBM)

Glioblastoma is one of the most lethal human cancers, accounting 82% of the
malignant gliomas (16, 20). Gliomas are more common in adults ages 45-65 and affect
men more than woman (American brain tumor association/ABTA). Based on the
11

histology of the tumor, the World Health Organization (WHO) has classified
glioblastoma as grade IV tumor of the Central nervous system (20-22). These tumors
are heterogeneous and characterized by high mitotic activity, microvascular
proliferation and necrotic areas. Clinical, histological and radiologic evidences suggest
that the primary GBM arise de novo whereas the secondary GBM arise from the
progression of pre –existing lower grade gliomas (23). Primary tumors most commonly
arise quickly and are very aggressive. These tumors account for the majority of
glioblastoma and occur in persons age 55 or older. Secondary tumors are usually
found in persons age 45 or younger, normally start as low grade glioma and ultimately
transform into malignant rapidly growing gliomas.

These tumors are highly invasive and the tumor cells invade into the surrounding brain
parenchyma but do not metastasize (20, 22). As the tumor cells invade the surrounding
brain, complete surgical resection of the tumor is not possible. The standard care for
patients who have been newly diagnosed with GBM includes surgical resection
followed by concurrent adjuvant radiotherapy in combination with the chemotherapeutic
agent Temozolomide (TMZ, alkylating agent); but still less than 5% of the patients
survive less than 5 years (24-27). TMZ have the ability to methylate DNA, leading to DNA
damage which triggers the death of tumor cells. However, some cells have an ability to repair
this type of DNA damage by expressing a protein O6-alkylguanine DNA alkyltransferase (AGT)
encoded in humans by the O-6-methylguanine-DNA methyltransferase (MGMT) gene. In some
tumors, MGMT is epigenetically silenced preventing the synthesis of this enzyme and thereby
making the tumors more sensitive to TMZ. A recent study has suggested that methylation

of the promoter of O6-methguanine-DNA methyl transferase (MGMT) has a survival
advantage upon chemotherapy with TMZ when compared to the unmethylated
12

promoter status of MGMT (27). This study has established that MGMT promoter
methylation can be used as a strong predictive marker. There are currently three
molecular markers that are being used routinely in the clinic which include mutations in
the isocitrate dehydrogenase 1 and 2 (IDH1/2), codeletion of 1p and 19q chromosomes
and MGMT promoter methylation (10, 28, 29). These markers have diagnostic,
prognostic and predictive value and have gained significant clinical relevance. A better
understanding of the cellular origin and the molecular pathways that regulate these
tumors needs to be elucidated.
The recurrence of the disease is mainly due to invasive cells that are radio and chemoresistant, especially the cancer stem cells (CSCs). Studies have shown that
heterogeneous tumors are composed of tumor cells and a small percentage of cancer
stem cells. Cancer stem cells constitute around 2%-3% of the tumor mass. The CSCs
are highly tumorigenic and have self-renewal potential (30). CSCs are phenotypically
similar to the normal stem cells, expressing the genes that are the characteristic
features of neural stem cells and express CD133 gene. The CD133

+

cells have a

higher DNA repair capacity when compared to normal cells as the gene down regulates
autophagy genes (31, 32). Studies have also shown that as few as 100 CD133+ cells
when implanted into the brain of immunodeficient (SCID) mice can reproduce tumors
but a million CD133- cells cannot reproduce the same tumor (33). Usually CSCs are in
the quiescent state, but upon surgery, radiation or chemotherapy, they are stimulated
and proliferate exponentially and are responsible for tumor recurrence.
In an effort to better understand the genomic changes that occur in glioblastoma, the
cancer genome atlas research network (TCGA) compiled molecular profiles on GBM
patient samples and found that when looking at gene expression and mutation data,
13

that GBM could be classified into four subclasses: proneural, neural, classical and
mesenchymal (8, 21, 34, 35). The proneural subclass is characterized by the
amplification of platelet derived growth factor receptor -α (PDGFRα) and also
expresses several proneural development genes, the neural subclass is characterized
by the presence of neural markers, classical group by the amplification of Epidermal
growth factor receptor (EGFR) and cdkn2a deletion, and mesenchymal group by the
loss of neurofibromin (NF1)(8, 21, 34, 36, 37). This classification has helped to
understand the molecular signature of GBM but did not provide any prognostic tool or
survival advantage.

Figure 1: Molecular subtypes of GBM. In an effort to better understand the genomic
changes that occur in glioblastoma, TCGA did molecular profiles on GBM patient
samples. Based on the gene expression and mutation data GBM could be classified
into four subclasses. The four subtypes are Proneural, Neural, Classical and
Mesenchymal. Figure is taken from reference (38), with the following license number
3626010907812.
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1.3 REST
The Repressor Element-1 (RE-1) silencing transcriptional factor (REST), also
known as neuron restrictive silencing factor (NRSF), is a major transcriptional
repressor of neurogenesis in neural cells and neuronal differentiation in non-neural
cells (39). REST is expressed at higher levels in neural stem cells (NSC) and
embryonic stem (ES) cells and thereby prevents them from neuronal differentiation
(40, 41). In mature neurons, REST is expressed at very low levels. REST
expression is preserved in NSCs and ESCs to ensure these cells maintain stem cell
properties (39, 42, 43). Studies have shown that REST is important for normal
brain development, and homozygous deletion of REST resulted in embryonic
lethality at E11.5 (44). Most of the studies to date have shown the role of REST in
embryonic development and neurogenesis. In addition, dysfunction and abnormal
expression of REST has been found in Downs syndrome, Huntington’s disease and
medulloblastoma(42).
REST is a 116 kilo Dalton (kDa) kruppel type zinc finger transcriptional factor that
contains a central DNA binding domain (Zn-DBD) consisting of eight zinc finger
motifs, that binds to the consensus RE1 (or NRSE) sequence on the target genes
regulatory regions(43, 45, 46). It contains two distinct repressor domains (RD): one
at the N-terminus (RD1), and the other within the zinc finger motif at the C-terminus
(RD2)(43, 45). The central DNA binding domain can recognize two types of RE-1
motifs on the target genes; a) canonical RE-1 motif and b) non-canonical RE-1 motif
(47, 48). The canonical and the non-canonical motif differ in the length of the
insertion between two conserved sequences. The former is characterized by the
presence of a single nucleotide that separates the conserved sequences while the
15

later has variable length of non-conserved nucleotides. The canonical motif has a
higher binding affinity to REST suggesting tissue specific functions. The repressor
domain RD1 interacts with mSin3A while RD2 interacts with Co-REST (43, 49).
Both RD1 and RD2 repressor domains recruit the histone deacetylase (HDACs)
silencing complex to remodel chromatin and represses its target gene expression
(43, 49) . A recent study using a combination of in silico and biochemical
approaches has identified 1,892 human, 1,894 mouse, and 554 Fugu RE-1 sites on
target genes (47).

RD1

DBD

RD 2
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Figure 2: Structure of REST protein. REST contains a DNA binding domain
(DBD) with eight zinc finger domains and two repressor domains (RD1 and RD2).
REST recognizes RE1 consensus sequence on the target gene regulatory
elements. (Adapted from (39, 45) )
REST is regulated by ubiquitin mediated proteosomal degradation, βTransducin repeat containing protein (β-TRCP) an E3 ligase, promotes REST
degradation during the G2 phase of cell cycle in ES cells and non-neural cells(50,
51). Failure to degrade REST attenuates the neuronal differentiation process in
neural cells. Studies have also identified the ability of USP7 (herpes virusassociated ubiquitin specific protease) to compensate REST ubiquitination which
prevent differentiation through deubiquitination. Deubiquitination mediated by USP7
and the ubiquitination by β-TRCP together regulate the REST protein levels and its
function(52).
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Depending on the cellular context, REST can function either as a tumor
suppressor or oncogene. REST is expressed in non-neural tissues such as lung,
breast and colon epithelium and there by represses neurogenesis (53-56). Inhibition of
REST in epithelial cells has increased the capability for transformation. A mutant form
of REST, which lacks the c-terminus acts as a dominant negative isoform, when
transfected into colon cells promotes anchorage - independent growth. Most of the
non-small cell lung cancers (non- SCLC) have normal expression levels of REST at
protein and RNA level. However, around 10% of the cancers have loss of SWI/SNF
complex, a cofactor required for REST activity. Loss of function of REST is also
observed in other cancers like lung, prostate and breast and successive increase in
the neuroendocrine genes (53, 54). In non-neural tissues dysfunction or loss of REST
leads to neuroendocrine carcinomas suggesting REST contributes to tumor
development. In non-neural cancers REST acts as a tumor suppressor by regulating
cell proliferation and apoptosis. In human mammary epithelial cells (HMECs) knock
down of REST enhances Akt phosphorylation and inhibition of PI3K signaling and
there by reduces the transformation capability of the cells (50). Studies have shown
that in lung and breast cancers loss of function of REST enhances cell proliferation
and survival and up regulation of BCL-2 gene expression(42). Most of the studies to
date suggested that in non-neural cells or tissues REST has a tumor suppressor
function and inhibits growth. However a recent study has shown that conditional
deletion of REST in colon crypts increased the expression of REST-target genes but
no significant effect on tumor development is observed(57).
As REST plays an important role in maintenance of NSCs, functional
abnormality of REST is found in the development of many brain tumors. Interestingly,
17

elevated levels of REST protein have been observed in neuroblastoma and
medulloblastoma tissues when compared to the surrounding normal tissue. The higher
expression levels of REST in medulloblastoma and neuroblastoma correlate with poor
patient survival (42, 56, 58). REST mainly acts as a oncogenic promoter in brain
tumors. Studies have shown that ectopic expression of mutant REST, REST-VP16 in
medulloblastoma cells have significantly reduced the tumorigenic potential of these
cells (59). Inhibition of REST in medulloblastoma leads to apoptosis. A recent study
has shown that REST regulates hedgehog signaling during embryonic development.
Hedgehog signaling regulates the proliferation and differentiation of neural stem cells.
Also, during medulloblastoma development there is an up regulation in the hedgehog
signaling. Studies have also shown that Wnt signaling pathway that controls properties
of neural stem cells also regulate the expression of REST. Thus a cross talk between
these 3 signaling cascades plays an important role in medulloblastoma tumorigenesis.
REST has very tissue specific function. Inhibition of REST in epithelial cells leads to
increased proliferation while in medulloblastoma cells leads to increased apoptosis
(59-61). Studies have shown that REST requires additional partners or oncogenes to
promote tumorigenesis of medulloblastoma. Over expression of REST alone doesn’t
promote medulloblastoma tumor formation. Rather co-expression of c-myc is required
to promote the formation of medulloblastoma tumors (62). Studies have clearly show
that REST has opposing functions in different tissues; it acts as a tumor suppressor in
epithelial cells and as an oncogene in brain tumors. The tissue specific roles of REST
might be attributed to forming different repressor complexes with its co activators. As
REST plays a crucial role in maintenance of neural stem cells and also development
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of brain tumors, it is critical to develop a novel therapeutic approach specifically
targeting REST in cancer cells.

1.4 MicroRNAs
MicroRNAs are small molecules of 20-22 nucleotides endogenous noncoding
functional RNAs (63-65). They regulate gene expression either by regulating mRNA
translation or degradation of specific mRNAs that control cellular processes.
Computation and experimental approaches have discovered that a single microRNA
can target more than 100 genes mRNA. Studies have shown that 60% of the
human protein coding genes are predicted to contain miRNA binding sites in their
3`- untranslated region (UTR ) (64). MicroRNAs activity is primarily through binding
to the 3`UTR of messenger RNAs resulting in degradation and translational
repression. microRNAs do not require perfect base pairing unlike other small RNAs
but can regulate anetwork of specific genes. However studies have also reported
binding and activity through the 5`-UTR .(66)
A high-throughput screen and functional studies in cancer has
revealed that miRNAs play important roles in human disease. A small change in the
expression levels of microRNA has significant effect on the mRNA targets.
MicroRNAs were found to affect cellular proliferation, apoptosis, invasion,
angiogenesis, and stemness of the malignant cells. MicroRNAs can be either tumor
suppressors or oncogenes based on their expression in malignant tissue compared
to the surrounding normal tissue.

19

Accumulating evidences has shown that miRNA expression can be
used as a prognostic or diagnostic marker in cancers. It has been shown that
classification of cancers based on their

miRNA expression signature is more

accurate than their mRNA based signature (29, 67). It is easy to modulate the
expression of microRNAs either using antisense oligonucleotides or precursor or
mimic sequences. The expression profiles of microRNAs differ between the normal
tissue and tumor tissue and between tumor types.

Studies have shown that

aberrant microRNA expression can affect cell proliferation, apoptosis, invasion and
epithelial to mesenchymal transition(63). Additionally, studies have identified
correlations between microRNA expression and recurrence and survival.
Genome wide analysis and high throughput screenings have
revealed that some MiRs have RE1 binding sites. Studies have also shown that
miR-21 is expressed at higher levels in glioblastoma and has survival significance
(68). Studies have shown that REST regulates the expression of miRs that promote
neuronal differentiation including miR-124a, miR-9 and miR-132 (42).
Based on binding studies and expression analyses, miR-124a was one
of the earliest identified miRs demonstrated to be a direct target of REST. Studies
have shown that in NSCs and non-neural cells REST represses miR-124a
expression, thereby preventing neurogenesis and expression of neuronal genes.
Two independent studies have shown that treatment of GBM stem cells with miR124 led to differentiation of these cells and decreased expression of stem cell
maintenance proteins(69). This result suggests us that low expression level of miR124 in the GBM patient’s results in decreased differentiation and increased
proliferation of GBM stem cells.
20

miR-124 is one of the abundant microRNAs in the brain and is often
down regulated in GBM patients. Studies have shown that addition of miR-124 in
the cells that lack them reduces the migratory and invasive potential (69, 70).
MicroRNA, miR-203

has been identified as a tumor suppressor

microRNA in basal cell carcinomas and hepatocellular carcinoma (71-74). Studies
have shown that miR-203 is epigenetically silenced in hepatocellular carcinoma
tumors and leukemias (72, 75). Studies have also shown that it is over expressed in
pancreatic adenocarcinoma and shows correlation with poor prognosis (76). MiR203 has been shown to be up regulated upon UV radiation indicating its role in
apoptosis (77). Studies have shown that role of microRNAs in malignancy is due to
translocation of chromosomes or allelic deletions. Recent evidences have shown
that the 14q chromosome harbors a multiple tumor suppressor genes and plays an
important role in GBM pathogenesis. This region harbors several microRNAs
including miR-203. Two independent studies have shown that there is a

allelic

deletion on chromosome 14q in 20%-40% patients (78, 79).

1.5 Glioblastoma Stem cells (GSCs)

The recent beginning of the “cancer stem cell” hypothesis has brought a new
perspective to our understanding of GBM biology and therapy (11, 14). According to
this hypothesis, GBM tumors contain stem-cell-like cells, known as glioblastoma
stem cells (GSCs), which have the capacity for long-term self–renewal. GSCs are
more efficient at forming tumors than non-stem cells and are highly resistant to
chemo and radiation therapies and are believed to be responsible for tumor
21

recurrence. Several studies have demonstrated that GSCs promote tumor
angiogenesis and invasion.
The glioblastoma stem cells (GSCs) used in the current study are derived from
the patient tumors that are treated at MD Anderson Cancer Center, for GBM after
getting patients consent. The tumors are washed and subjected to enzymatic
dissociation and allowed to recover in a medium that promote only stem cell growth.
Our research suggests that REST is expressed at varying levels in these GSCs
established from patient tumors and helps in maintaining their self-renewal and
oncogenic properties like proliferation, apoptosis and invasion (17). This shows the
heterogeneity of these established cell lines. These GSCs can recapitulate the
human tumor when implanted into the mice brains.
Based on the REST protein expression levels our lab has classified the GSCs
available as High REST (HR-GSC) and Low REST (LR-GSC) GSCs. We observed that
GSCs with higher REST expression had a higher self-renewal capacity, sphere forming
capacity and oncogenic properties when compared to GSCs with lower REST
expression. Studies have suggested targeting REST for proteosomal degradation may
disrupt the oncogenic potential of GSCs.
In order to study the role of REST in self-renewal and GBM tumorigenesis we knocked
down REST in the HR-GSCs and performed self-renewal and tumorigenic assays. Our
group and two other groups have observed that upon knocking down of REST there is
a decrease in the self-renewal capacity, decreased proliferation, increased apoptosis
and decreased invasion both in vitro and in vivo. When REST knock down GSCs were
implanted into the brains of nude mice there is an increased survival of the mice when
compared to the controls. The tumors formed by HR-GSCs are highly invasive but
22

upon REST knock down the tumors are more circumscribed. Our studies along with
two other groups indicated that REST is involved in glioblastoma tumorigenesis (1719). However, the mechanisms by which REST regulates these tumorigenic properties
of GSCs are still unclear.

REST

Proliferation

Apoptosis
Apoptosis

Invasion

Tumorigenesis

Figure 3: REST regulates oncogenic properties of Glioblastoma Stem cells
(GSCs). When REST is expressed at higher levels there is an increase in level of
proliferation and invasion and decreased apoptosis leading to increased tumorigenesis
both in vitro and in vivo. When REST is expressed at lower levels there is decreased
proliferation and invasion and increased apoptosis leading to decreased tumorigenesis
both in vitro and in vivo.
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Chapter 2: Material and Methods
2.1. Cell culture
GSCs used for this study were obtained from the Brain Tumor center core, and were
established from human GBM surgical specimens from patients treated at
The University of Texas MD Anderson Cancer Center, Houston, TX as described
previously (17). The cells are maintained in Dulbecco’s modified Eagle’s medium
(DMEM) F12 (Sigma) supplemented with B-27 (1:50, Gibco), L-glutamine (1:100,
sigma), 20 ng/ml epidermal growth factor (Sigma), 20 ng/ml fibroblast growth factor,
and Penstrep (1:100) as previously described (17). Cells were maintained at 37°C with
5% CO2. These cells were grown as spheres, fed every 2 days, and split in half once
the sphere size reached 100 µm with Accutase (Sigma) and seeded as single cells.
The cells are frozen as single cells in 10% FBS, 20% DMSO and 70% basal medium
with no growth factors.
2.2. siRNA transfections
All siRNA transfections were performed using Amaxa nucleofector technology (Lonza)
.Four million cells were suspended in 90µl of amaxa buffer. 10µl of siRNA at a
concentration of 20µg/µl is added to the amaxa buffer to make a final volume of 100µl.
The samples are subjected for electroporation and immediately resuspended in 500µl
fresh medium. siNT (control/non targeting )and siRest siRNAs are obtained from
dharmacon (GE Health care).
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2.3. Total RNA isolation
Total RNA was extracted from the GSCs using Trizol reagent (Invitrogen, Carlsbad,
CA) according to manufacturer’s instructions. Briefly the cell pellets are lysed using 1ml
of Trizol reagent followed by chloroform extraction by centrifugation at 13,000rpm for
15 min at 4° C. The aqueous phase was collected and precipitated with equal volumes
of isopropanol. Glycogen is added at 1mg/1ml at this step as it aids in precipitation. The
samples were further centrifuged at 13,500 rpm for 15min at 4°C. The pellet were
washed with 1ml of 70% RNAse free ethanol and centrifuged at 7500rpm for 5min at
4°C. The pellets are air dried and resuspended in RNAse free water. Concentration of
RNA was determined by spectrophotometric analysis using Nanodrop (Thermo
scientific, Rockford, IL). The samples are stored at -80°C for future use.
2.4. Genome-wide expression analysis of GSCs with loss-of-function of REST
(Microarray)
Total RNA was extracted from the transient transfections of siRest and siNT cells.
RNA purity was assessed using Nanodrop spectrophotometric measurement of optical
density (OD) 260/280 ratio of greater than 1.85. miR microarray was performed
(Affymetrix, U-133 plus 2.0 array) by

labelling and hybridizing using five hundred

nanograms of the total RNA according to manufacturer’s protocol. Bioinformatic
analysis was performed by using R (2.14.2) program to identify the miRs with a two fold
increase upon REST knockdown with a significant p value (p<0.05)
2.5. Western blotting
Whole cell extracts were prepared by using lysis buffer ((150mM NaCl, 25mM Tris, p H
7.5,5mM EDTa,1% Triton X,0.1% SDS,0.5% sodium deoxycholate) with 1X protease
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inhibitors. Briefly, after the addition of lysis buffer the samples were kept on ice for 30
minutes with frequent vortexing every 5 minutes. The samples were centrifuged at
13,000rpm for 15 minutes. The supernatant was collected and quantified using a BCA
protein assay reagent kit (Pierce Biotechnology, IL). Samples were resolved by loading
50 µg of the lysates onto gradient HEPES gels (Pierce Biotechnology, IL). The proteins
are transferred to a nitrocellulose membrane and blocked with 5% milk followed by
incubation with rabbit anti-REST antibody (Millipore, USA) overnight at 1:1000 dilution
or mouse anti-actin (1:10,000) and then incubation with fluorescent-labeled secondary
antibody for 1 hour. The membranes were scanned using the Licor program (Odyssey
detection system) to visualize the protein complexes.
2.6. Reverse Transcriptase Polymerase chain Reaction (RT-PCR)
Complementary DNA (c-DNA) was synthesized by using 1µg of total RNA using the
verso c-DNA synthesis kit (Thermo Scientific) according to manufacturer’s instructions.
Briefly, 4µl of 5X cDNA synthesis buffer, 2 µl of 10mMdNTPs, 1ul of primer (1:3 ratio of
oligo dT and random hexamers), 1µl of RT enhancer and 1µl of verso enzyme and 1µg
of total RNA diluted in water to make a total volume of 20µl. Reverse transcription was
done at 42°C for 30min.
2.7. Quantitative real-time PCR
The c-DNA synthesized was diluted to bring to a working concentration of 5ng/µl.
Quantitative PCR (qPCR) was done using SYBR green master mix (Applied
biosystems,CA) and primers for the 7 microRNAs identified in the screen (miR-124
,miR-136, miR-203,miR-518e,miR-545,miR-557,miR-942). Primer sequences are
shown in the Table. Analysis was performed on ABI 7900 real time PCR system
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(Applied biosciences). Relative miRNA measurements were done using delta Ct
method as described previously(80). All the experiments were done in triplicates
List of miR Primers that are potential targets of REST
Table 1: Primers for validation of microarray results by qRT-PCR
Primer

Forward Primer

Reverse Primer

miR-124

5`-TCCGTGTTCACAGCGGAC-3’

5`-CATTCACCGCGTGCCTTA-3’

miR-136

5`-

5`-

GGACTCCATTTGTTTTGATGATG-

AGACTCATTTGAGACGATGATGG-

3’

3’

5`-

5`- GGTCTAGTGGTCCTAAACATT-

TCCAGTGGTTCTTAACAGTTCA-3’

3’

miR-518e

5`- GTTTTCTCAGGCTGTGACC-3’

5`- GTGTGTTCTCAGGCTGTGAC-3’

miR-545

5`- TTGCCCAGCCTGGCACCAT-3’

5`- GTTTTTCCCAGCTGGCA-3’

miR-557

5`-

5`- TTGTTCATGCTAAGAAT-3’

miR-203

GTAGAATGGGCAAATGAACAGT3’
miR-942

5`-

5`- TGTGTGATTAGGAGAGTATC-3’

GGATTAGGAGAGTATCTTCTCT-3’
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2.8. Taqman assays to measure miR-124 and miR-203 expression
Total RNA was extracted as described in total RNA isolation section of the methods.
Mature microRNA expression levels of miR-124 and miR-203 were quantified using
Taqman®microRNA

(Applied

Biosystems,

CA).

Taqman®

MicroRNA

reverse

transcription kit (Applied Biosystems, CA) was used to synthesize cDNA using specific
primers for miR-124, miR-203 and Sno135 according to manufacturer’s protocol. The
quantitative PCR was performed using Taqman® universal master mix with No Uracil
N-Glycosylase( UNG) ( Applied Biosystems, CA) on ABI 7900 real time PCR machine
(Applied biosciences). Relative expression levels of miR-124 and miR-203 were done

2.9. Chromatin Immunoprecipitation (ChIP) Assay
GSCS dissociated into single cells by accutase were cross-linked at room temperature
for 10 minutes using 2%formaldehyde. Cross linking was stopped by the addition of
1/10 volume of 1.4M glycine and rocking for 5 minutes. The cells are washed in 5ml of
1XPBS by spinning at 1200rpm for 2 minutes. The pellets were rewashed in 10ml of
fresh PBS with 100µl of protease inhibitor and sonication wash buffer (10mM HEPES,
pH 7.5, 200mM NAcl,1mM EDTA,0.5mM EDTA) . The pellets were resuspended in lysis
buffer (150mM NaCl, 25mM Tris, pH 7.5,5mM EDTA,1% Triton X,0.1% SDS,0.5%
sodium deoxycholate) and left on ice. The samples were sonicated with a continuous
pulse at 65 amplitude for 15 seconds for 13 cycles. A small portion of the sample is
reverse cross-linked and DNA is recovered and size of the DNA was determined. This
yielded us a higher concentration of DNA at 500bp with increasing amounts of smaller
fragments which indicated further sonication is not necessary. The samples were
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precleared for immunoprecipitation by incubating with protein A beads for 2 hours at 4°
C. The beads were collected by centrifugation and the supernatant is transferred to a
new tube. A small aliquot of the sample is saved as an input and the remaining sample
is divided into 2 equal aliquots for immunoprecipitation using anti-REST, anti-IgG
antibody. The samples were incubated overnight at 4 °C.

Any residual debris was

removed by centrifugation. To the supernatant fresh Protein A beads were added and
incubated for an hour at 4 °C. Beads were recovered by centrifugation and the
supernatant was stored at -80C for future use. Beads were further washed in RIPA
buffer (50mM Tris pH 8.0,150mM Nacl,0.1% SDS,0.5% sodium deoxycholate ,1% NP40,1mM EDTA) for 10 min and the supernatant was recovered by centrifugation.
Further the beads were washed with 1X high salt solution(50mM Tris pH 8.0,500mM
Nacl,0.1% SDS,0.5% sodium deoxycholate ,1% NP-40,1mM EDTA) to disrupt proteinprotein interactions. In order to break the RNA fragments the beads are further washed
with 1X LiCl wash (50mM Tris pH 8.0,250mM Licl,0.1% SDS,0.5% sodium
deoxycholate ,1% NP-40,1mM EDTA). The beads are washed in TE buffer (10mM Tris
pH 8.0,1mM EDTA) followed by proteinase K treatment to remove the bound proteins.
The samples along with the inputs were subjected to reverse crosslinking overnight at
65°C. The samples were extracted twice using equal volumes of phenol /chloroform.
The final aqueous phase is collected and the DNA is precipitated using 1/10 volume of
3M sodium acetate, 2.5 volumes of ethanol and glycogen (carrier molecule) and stored
at -80C for 2 hrs. DNA is collected by spinning at 13,000 rpm for 20 minutes followed
by washing with 70% ethanol. The pellets are air dried and resuspended in water and
stored at -20°C. PCR was performed after a 1:5 dilution of the samples. qRT-PCR was
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performed and the analysis was done by fold enrichment method as described
previously.
2.10. Identification and validation of REST response elements in the promoter
regions of miR-124/203
REST binding sites on the promoter region of miR-124 and miR-203 were determined
using Mat Inspector (Genomatix software suite v3.3), a tool that identifies
transcriptional factor binding sites. RT-PCR was performed by using primers specific
for the indicated regions as shown in the following tables
Table 2: List of primers for potential RE1 binding sites on the gene chromatin of
miR-124
Site

Forward Primer

Reverse Primer

RE1 site # 1

5`-

5`-ACCAGCACACGTCATTCTCA-3’

-2648bp

CCGCATTTTCCTTGGCACAG3’

RE1 site # 2

5`-

5`-TCCCCCAATCACACAGACAAT-

(Nonspecific) GGAAAAAGCCTGGATGCGAA- 3’
-300bp

3’
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Table 3: List of primers for potential RE1 binding sites on the gene chromatin of
miR-203
Site

Forward Primer

Reverse Primer

RE1 site # 1

5’- CGTCTAAGGCGTCCGGTA- 3’ 5’-

-223bp

GAGCTGCGGAGAGAGGAG3’

RE1site #2

5’-

-512bp

3’

GCCCAGACGAGACGGTTC- 5’CCGCGACTGATCCTCCAC3’

RE1site #3

5’- CACACCCACCGGAGAGCTA- 5’-

-762bp

3’

CCCGAACCGTCTCGTCTG-‘3

RE1 site # 4

5’-

5’-

-1223bp

CAACCCCATACAGACACACTAA- TGTCCAGGCCTGACCAGT-‘3
3’

RE1site
nonspecific

#5 5’- CCGTCCTCTCTCGTCAGT- 3’

5’-CTCCCAAAGTGCTGGATT3’

site

(-2167)

2.11. Dual Luciferase Assay
The reporter construct pRLTK along with the PGL3- basic vector or PGL-3 with RE-1
sites of miR-124 (site #1) or miR-203 (site #4), PGL3 with mutated RE-1 site on miR124 or miR-203 were co transfected into High REST and REST knock down cell lines
by Amaxa electroporation. The DNA fragment containing the REST binding site
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identified by chip was amplified from genomic DNA of HR-GSC2 line by PCR with 5’
XhoI and 3’ HindIII restriction sites.
Forward

Primer

5’-ATACTCGAGGGTGGCTGTGTTCTGGTCTG-3’

and

Reverse

primer 5’- ATAAAGCTTGCTAGCTCTCCGGTGGGT-3’. The mutant version is
generated using the quick change mutagenesis kit (Agilent technologies). 48 hours
post transfection luciferase activity was measured with dual –luciferase reporter assay
(Promega) according to manufacturer’s protocol.
2.12. Cell Transductions
Gain of function of miR-124/203: HR-GSC shNT cells have higher expression of
REST and lower expression levels of miR-124 and miR-203, so we used these cells to
over express miRs. The cells were transduced with either shNT control or premiR124/203 lentiviruses (Thermo scientific Fisher, USA). Transduction efficiency was
initially checked by fluorescence microscopy, as the vectors have a GFP tag.
Overexpression of the miRs was further confirmed by qRT-PCR.
Loss of function of miR-203: HR-GSC shREST cells have lower expression of REST
and higher expression levels of miRs. Cells were transduced using viruses for control
shNT or shmiR-203 (Genocopeia, USA). Knockdown was confirmed by qRT-PCR.
The generated and expression confirmed cell lines for both miR-124 and miR-203
overexpression and knockdown were used for assessing the cells tumorigenic
properties by performing proliferation, invasion, and apoptosis assays in vitro.
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2.13. In vitro Proliferation assay
Proliferation assays were performed on the control and miR-altered cell lines using a
colorimetric BrdU assay kit (Roche, Germany). Briefly, 3000 cells per well were seeded
8 hours before the BrdU labeling. The cells were incubated with BrdU labeling reagent
for 24 hours , fixed and DNA is denatured by the addition of fixadent (proprietary
solution, Roche ,Germany) which makes the labelled BrdU more accessible to the
antibody in the next step. The cells are incubated with anti-BrdU antibody for 2 hours.
The substrate was added and upon color development the color measured at 492 nm.
The intensity of the color developed is directly proportional to the amount of DNA being
synthesized and there by number of proliferating cells. All experiments were done in
triplicates.
2.14. In vitro cell death detection
The assays were performed using a cell death detection ELISA
Germany).

PLUS

kit (Roche,

The assay is based on the principle of using monoclonal antibodies

directed against DNA and histones. Briefly the lysates are plated onto streptavidin
coated plates and incubated with a mixture of anti-histone-biotin and anti-DNA-POD.
The anti-histone antibody binds to the immunocomplexes and at the same time binds to
the streptavidin coated on the plate with the cell lysate. The DNA POD antibody reacts
with the DNA of the nucleosome. The amount of POD is determined by using ABTS
substrate.
2.15. In vitro invasion assay
Invasion assays (BD biosciences) were performed on the control and miR-altered cell
lines as described previously

(17)

. Briefly, 5000 cells were seeded in the upper
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compartment of the control or invasion chambers. Ten percent fetal bovine serum was
added to the lower chamber, which acts as a chemo-attractant. Cells were incubated
for 24 hours at 37°C and 5% CO2. The chambers were fixed with methanol and stained
with crystal violet. Cells were counted under a microscope and compared to controls.
All experiments were done in triplicates.
2.16. Mouse orthotopic GBM models
All the mouse experiments were carried out according to protocols approved by the
Institutional Animal Care and Use Committee at The University of Texas MD Anderson
Cancer Center. Based on the power analysis for each cell type, eight nude mice 4-5
weeks old (obtained from the Department of Experimental Radiation Oncology at MD
Anderson Cancer Center) were used. The cells transduced with vector alone were
used as controls. Brain orthotopic tumor models were generated as described
previously (17). Briefly, 50,000 cells were implanted in a total volume of 5 µl into the
right frontal lobes of the mice as shown in figure 3. Prism 6.01 [Graph pad] was used
to generate the Kaplan Meir survival curves.
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Bolt

Altered GSCs are injected

45 days
10 days

Brains are collected
Paraffin embedded and
Tumorigenic assays

4-5 weeks of age
Figure 4: Implantable guide screw system for orthotopic brain tumor models.
Male nude mice of 4-5 weeks old are bolted with either plastic or metallic bolts and
allowed to recover for 10 days and altered GSCs are injected through the bolt. Tumor
growth is monitored by MRI imaging and the brain tissue is collected after 45 days. In
vivo assays are performed on the brain sections. Figure modified from (81)

2.17. In vivo proliferation assay
The paraffin sections were incubated at 60°C for 30 minutes. This allows the melting of
paraffin and binding of the tissue to the glass slide. Following this, the sections were
hydrated through alcohol grades after clearing with 3 times in xylene. Antigen retrieval
was performed with citrate buffer in a steamer for 20 minutes and allowed to cool for 1
hour. Sections were blocked in 5% goat serum for 1 hour followed by incubation with
human-specific NuMA antibody (1:100; Abcam) overnight at 4°C. After washing twice
with 1X phosphate-buffered saline plus 0.1% Tween-20, the sections were incubated
with Ki67 antibody (1:500, Dako Clone MB-1) for 1 hour and washed twice with
phosphate-buffered saline followed by incubation with secondary antibodies. The slides
were mounted with DAPI and double-positive cells (Ki67 and NuMA) were counted
from 10 different fields with the fluorescent microscope.
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2.18. In vivo apoptosis assay
In vivo TUNEL assay was performed according to the manufacturer’s instructions
(Roche, Germany). Briefly, after hydrating the paraffin sections through alcohol grades,
antigen retrieval was performed and the slides were blocked for 1 hour in 3% bovine
serum albumin and 20% fetal bovine serum. After washing, the slides are incubated
with TUNEL reaction mixture at 37°C in a humidified atmosphere followed by mounting
with DAPI. Positive cells were counted in 10 different fields.
2.19. In Vivo Invasion assay
Invasion potential of the cells was determined by staining with a NuMa antibody as
described in the section in vivo proliferation assay..
2.20. Statistical analysis
An unpaired two-tailed Student`s t-test was performed to evaluate the differences
between the control and treatment groups. All quantified data represent at least three
independent experiments.
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Chapter 3: Aim of the study
REST promotes oncogenic properties of GSCs both in vitro and in vivo. It affects the
survival of the tumor bearing mice. Earlier studies have found that REST is
overexpressed in class of medulloblastoma tumors causing the blockage of neuronal
differentiation. Deregulation of normal expression of REST leads to tumor formation.
The main goal of the project is to delineate the mechanism by which REST regulates
oncogenic properties in GSCs. REST is predicted to regulate more than 1000 genes, it
is crucial to identify the major downstream targets of REST that play an important role
in regulating the oncogenic properties of GSCs. We considered the microRNA targets
that are regulated by REST as they are fewer in number (1800) when compared the
genes (21,000).
Aim 1: To identify and validate the potential miR-targets of REST that play role in
GSC tumorigenesis
microRNA microarray was performed on siRest or siNT (control)

transfected HR-

GSCS. As REST is a transcriptional repressor we considered the microRNAs that are
up regulated upon REST knock down. We identified two potential microRNAs, miR124 and miR-203 that are regulated by REST. The identified potential REST targets
were validated by taqman assays and REST binding to the gene chromatin of these
microRNAs was confirmed by ChIP and luciferase assays.
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Aim 2:

To determine whether REST - miR-124 axis regulates oncogenic

properties of GSCs in vitro and in vivo
miR-124 was identified as one of the potential targets of REST from our screen. miR124 is the most abundant microRNA in adult and embryonic brain. Studies have shown
that REST functions as a negative regulator of miR-124 in NSCs. In this aim we tested
if miR-124 regulates oncogenic properties of GSCs and does the REST-miR-124 axis
has any role in GSC tumorigenesis. We performed LOF and GOF of miR-124 by
lentiviruses in GSC cells and performed in vitro and in vivo tumorigenic assays
(proliferation, invasion and apoptosis). We observed that over expression of miR-124
leads to decreased proliferation and invasion and increased invasion both in vitro and
in vivo. GOF of miR-124 has increased the survival in tumor bearing mice when
compared to its controls.

Aim 3:

To determine whether REST mediated control of miR-203 regulates

oncogenic properties of GSCs in vitro and in vivo
Another novel microRNA target that has been identified in our screen was miR-203.
This aim tests if REST-miR-203 axis regulates the oncogenic properties of GSCs both
in vitro and in vivo. LOF and GOF of miR-203 GSCs were made by lentiviral
transduction. Oncogenic potential of these cells was validated by proliferation,
apoptosis and invasion assays. We observed either overexpression or knock down of
miR-203 did not have any role in regulating the cell proliferation or apoptosis of these
cells both in vitro and in vivo.

But overexpression of miR-203 lead to decreased

invasion potential of these cells both invitro and in vivo. Also, overexpression of the
miR-203 in these cells led to increased survival of the tumor bearing mice.
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REST
miR-124 ?

Proliferation

miR- 203 ?

Apoptosis
Apoptosis

Invasion

Tumorigenesis

Figure 5: Schematic representation of REST regulatory circuit in tumorigenesis.
REST might be regulating the tumorigenesis of GSCs either through either of the miRs
or both the miRs.
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Chapter 4: Identification and validation of REST-miR targets that may play a role
in GSC tumorigenesis

Rationale
As reviewed in the introduction, our group and two other groups have shown that REST
regulates the oncogenic properties of GSCs (17, 18). When REST is expressed at
higher levels there is an increase in cell proliferation, invasion, self-renewal and
decrease in apoptosis both in vitro and in vivo. GSCs with high REST(HR-GSCs)
produced more infiltrative tumors while low REST GSCs (LR-GSCs) produced
circumscribed tumors. A schematic representation of REST regulating oncogenic
properties is shown in figure 3. REST regulates survival in orthotopic mouse tumor
models. However, the mechanistic understanding of the REST driven self-renewal and
oncogenesis needs further elucidation. REST is predicted to regulate more than 1000
genes, it is crucial to identify the major downstream targets of REST that play an
important role in regulating the oncogenic properties of GSCs . Hence, the identification
of mechanism(s) by which REST regulates oncogenic properties of GSCs will foster
development of targeted therapy downstream of REST.
In this section, we identified the potential microRNA targets of REST that might play a
role in GSC tumorigenesis by performing a microRNA microarray on REST loss of
function cells. The identified microRNA targets were first validated by qRT-PCR to
confirm the microRNA microarray results. Two potential microRNAs, miR-124 and miR203 were identified and validated. Taq man assays were performed to find the
expression levels of mature microRNAs in both loss and gain of function of REST cells.
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REST binding to the gene chromatin of the miRs was further confirmed by ChiP assay
and luciferase assay. Together our data suggest that miR-124 and miR-203 are the
potential microRNA targets of REST and are differentially regulated with REST
expression.

Results
REST directly targets miR-124 and miR-203 and forms the REST-miR-124/ RESTmiR-203 axis
To determine potential miR targets of REST in GSCs, we performed genome wide
profiling

using

microRNA

microarray.

To

represent

REST

loss

of

function

manipulations, we transiently transfected two high-REST (HR)-GSC cell lines (HRGSC1 and HR-GSC2), with small interfering RNA Rest, (siRest) or a non-targeting
control (siNT). A total of four cell lines: HR-GSC1/siNT, HR-GSC1/siRest, HRGSC2/siNT, and HR-GSC2/siRest were generated. We used siRNA in these
experiments to identify the potentially immediate direct targets of REST. We then
performed a genome-wide miR expression analysis,

As REST is a repressor

transcriptional factor we looked into the microRNAs that are up regulated when REST
is knocked down with a fold change of 2 or more with a significant p value of p<0.05.
Whereas 128 miRs in HR-GSC1 and 43 miRs in HR-GSC2 had higher expression in
the siRest-treated cells than in the siNT controls, only seven miRs were common
between HR-GSC1 and HR-GSC2 in this differential analysis, as shown in (Fig 6). A
tabular representation of the 7 microRNAs that are up regulated upon REST knock
down, their fold changes in each cell line and chromosomal locations is shown in table
4.
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Figure 6: Venn diagrammatic representation of the microRNAs that are up
regulated upon REST knock down in both the cell lines. In HR-GSC 1 and HRGSc2 128 and 43 microRNAs are upregulated upon REST knock down. There are 7
microRNAs that are common in both the lines.

Table 4: Tabular representation of microRNAs that are up regulated upon REST
knock down. Upon REST knock down in both HR-GSCs, 7 microRNAs are
upregulated with a fold change of 2 or more.
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We first validated the microRNA microarray data by performing qRT-PCR. We
observed that microRNAs miR-124 and miR-203 were up regulated in both the HRGSCS upon REST knock down with a significant p value (p< 0.05). On the other hand
the other microRNAs are not up regulated in both the cell lines with a significant p value
(Fig 7).
Interestingly, miR-124, a well-known target of REST with a critical function in
neurogenesis was also identified in our screen. The capture of only a few miRs by this
analysis suggested that most of the REST miR targets are cell-line dependent and that
REST function is highly context dependent, as we found earlier.

Figure 7: Validation of microRNA microarray by quantitative real time PCR (qRTPCR). Seven microRNAs that are found be upregulated upon REST knock down were
validated by qRT-PCR. miR-124 and miR-203 expression was significantly upregulated
upon REST knock down in both the lines when compared to the others. Expression of
miR-557 and miR-942 was not detected.
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Two High REST cell lines are transduced with shRest or shNT lentiviruses (HRGSC1shNT, HR-GSC1shRest, HR-GSC2 shNT, HR-GSC2shREST). REST expression
was confirmed by western blotting in loss of function of Rest cells. From the same cells
total RNA was extracted and the expression of miR-124 and miR-203 was confirmed by
taq man assays. Both miR-124 and miR-203 were up regulated upon REST knockdown
in both the GSCs as shown in Fig (8A & 8B)

A

B

Figure 8: miR-124 and miR-203 are upregulated upon REST knock down.

A. Confirmation of REST knockdown in both the HR-GSC lines by western blotting. B.
Upregulation of miR-124 and miR-203 is observed upon REST knockdown with a
significant p value.
To further confirm the results obtained by REST loss-of-function manipulations, we
performed REST gain-of-function manipulations in two low-REST (LR)-GSC lines by
introducing either exogenous REST or the green fluorescence protein (GFP) control
and confirmed the REST overexpression using Western blotting as shown in Figure 9.
We determined the expression levels of miR-124 and miR-203 in these cells by taq
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man assays.

As shown, overexpression of REST consistently suppressed the

expression of miR-124 and miR-203 in both the LR-GSC lines ( Fig 9 A & 9B).
B
A

Figure 9: miR-124 and miR-203 are suppressed upon REST overexpression.
A. Immunoblot confirmation of REST expression in REST overexpression LRGSCs. B. Taqman assays was performed to measure the relative expression
levels of both the miRs. Both the microRNAs miR-124 and miR-203 were
suppression upon REST overexpression.
To confirm whether miR-124 or miR-203 expression was suppressed by direct binding
of

REST on the gene chromatin, we performed bioinformatic analysis using

matInspector (Genomatix software suite) to determine potential REST binding sites
(RE1s) present on the miR-124 or miR-203 promoter elements 3000bp upstream and
downstream of the miR-124 or miR-203 start site. We then performed chromatin
immunoprecipitation (ChIP) analysis using either REST or IgG (control) antibody. qRTPCR was performed using primers corresponding to sites present on the miR-124
promoter elements site # 1 (-2648) and site #2 (-300) (non-specific) upstream of the
Transcriptional start site (TSS) and miR-203 promoter elements: site # 1 (-223), site #2
(-512) , site # 3 (-762), site # 4 (-1223) upstream of the TSS , the potential RE1 site
and an additional random site, site #5. REST was found to bind to site #1 gene
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chromatin of miR-124 and only at site #4 of miR-203 indicating specific REST binding
sites.(Fig 10A & 10B)

A

B

Figure 10: miR-124 and miR-203 are the transcriptional targets of REST. Predicted
RE1 binding sites upstream of miR-124 and miR-203 TSS are represented (A &B).
ChIP was performed in HR-GSC with anti-REST antibody or and IgG control followed
by qPCR analysis using primers specific for the predicted RE1 sites upstream of miR124 or miR-203. Student’s t test was performed to determine the statistical significance.

To determine whether the single REST binding site present in the miR-124 or miR-203
gene chromatin directs REST-dependent expression, we sub cloned the site in front of
a luciferase reporter gene. For comparison, we also used no site or a mutated version
of the site.

We then transfected the plasmids in HR-GSC1/2/shNT and HR-

GSC1/2/shRest cells and determined luciferase activity in the resulting cells. Results
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shown in

Fig. 11 indicated that when no site was present or when the site was

mutated, luciferase activity was similar in the shNT- and sh/Rest-expressing HR-GSC
cells. In contrast, when the REST binding site was present, luciferase activity was
higher in shRest-expressing cells than in shNT-expressing cells. Thus, taken together,
these results indicated that REST directly targets miR-124 and miR-203 in GSCs.
A

B
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C

D

Figure 11: REST targets miR-124 and miR-203 gene expression through specific
sites on gene chromatin. A & B: We performed reporter gene analysis using a
plasmid containing luciferase gene downstream of wither the specific REST binding site
present on the miR-124 gene chromatin, a mutated version of the site or no site
transfected into HR-GSC1sh NT,HR-GSC 1 shREST (A), HR-GSC2 shNT,HR-GSC2
shREST (B) cells and measured the luciferase activity. Similar experiment was
performed with the miR-203 gene chromatin binding region (C &D). Luciferase activity
remained unaltered when an empty vector was expressed in either shNT or shREST
expressing cells, it increased in shREST when compared to shNT when the plasmid
contained the REST binding site. The increase of the activity is further reversed when
the plasmid contained the mutated binding site.

Both the microRNAs miR-124 and miR-203 are identified as potential targets of REST
that might play a role in GSC tumorigenesis. Both these microRNAs are identified as
tumor suppressor microRNAs in other cancers. Studies have shown that both these
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microRNAs are highly repressed in GBM tumors when compared to normal brain.
Studies have also shown that miR-124 plays a important role in migration and invasion
in glioblastoma. Loss of miR-124 leads to stem cell like traits and more invasiveness of
these cells. miR-124 is a known target of REST in NSCs and ES cells. Studies have
shown that miR-124 targets cyclin dependent kinase 6(CDK6) and there by regulates
the cell cycle. miR-203 is found to be highly repressed in hepatocellular carcinomas
and hematological malignancies. Ectopic expression of these microRNAs miR-124 and
203 in hepatocellular carcinomas resulted in inhibition of cell proliferation.
The microRNA miR-124 is already a known target of REST in NSCs and ES cells but
its role in GSCs is not known. MiR-203 is a novel target of REST identified in our
screen. So we decided to investigate independently on the two axes REST-miR-124
and REST-203 have any role on GSC tumorigenesis.
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Summary
Our data suggest that upon REST knock down there is an up regulation in the
expression levels of miR-124 and miR-203 in GSCs. Also, upon REST overexpression
there is a down regulation of both these microRNAs. We have also shown that REST
binds to the RE-1 sites located at 2.6kb and 1.2kb upstream of the TSS for miR-124
and miR-203 respectively. Our findings from luciferase assay further confirmed that
there is an increase in the luciferase activity in the presence of REST binding site in
shREST cells when compared to its controls (shNT). In contrast, when no binding site
was present or when it was mutated there was no difference in the luciferase activity in
REST knock down cells (HR-GSC shRest) and its controls (HR-GSC shNT). These
results indicate that REST directly targets miR-124 and miR-203 in GSCs.

50

Chapter 5: REST-miR-124 axis regulates oncogenic properties of GSCs in vitro
and in vivo

Rationale
In the previous section, we identified miR-124 as a potential target of REST. We
observed a reciprocal relationship in the expression of the microRNA miR-124 and
REST. We further determined that REST binds to the RE 1 sites located at 2.6kb
upstream of the TSS of miR-124 gene chromatin. This was further confirmed by
luciferase assays. The microRNA, miR-124 mature sequences are highly conserved
and are the most abundant miRNA in adult and embryonic brain. Based on binding and
expression studies, miR-124 was identified as one of the earliest miRs to be a direct
target of REST. Studies have shown that miR-124 is a part of REST regulatory network
in neural and non-neural cells where REST represses miR-124 expression, thereby
prevents neurogenesis and allows expression of non –neural genes. Studies have
shown that miR-124 is up regulated during differentiation of NSCs. miR-124 is up
regulated during neuronal differentiation and promotes cell cycle exit by inhibiting cyclin
D, a cell cycle regulator. A miR microarray study by Sibler et al and a
immunohistochemical study by Fowler has shown that miR-124 is down regulated in
gliomas relative to the normal brain (82, 83). Furthermore, down regulation of miR-124
correlates with poor survival in colorectal cancers.
In this section we investigated if the REST-miR-124 regulatory axis regulates
oncogenic properties of GSCs both in vitro and in vivo. We studied this hypothesis by
generating cell lines (2 independent cell lines) with loss and gain-of-function
(LOF/GOF) of miR-124 gain by lentiviral transductions. Expression levels of miR-124
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were confirmed by taqman assays and tumorigenic assays were performed both in vitro
and in vivo. We performed proliferation, apoptosis and invasion assays in vitro on LOF
and GOF miR-124 cells. After characterizing the cells in vitro we implanted the cells
into the brains of nude mice and performed Kaplan Meir survival analyses. Further, we
performed proliferation, apoptosis and invasion assays on tumor sections.
Confirmation of over expression or knock down of miR-124 expression
Two independent HR-GSCs and their respective REST knock down cells were
obtained and cultured. A schematic representation of experimental design is shown in
figure 12.

Figure 12: Schematic representation of experimental design. High REST GSCs
have higher expression levels of REST and low expression of miR-124. We used this
line to overexpress the miRs using lentiviruses. The REST knock down lines have
lower expression of REST and are high levels of miR-124. Lentiviral knock downs of
the miR-124 were performed in REST knock down lines.
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Gain of Function: HR-GSCs have higher expression levels of REST and lower
expression of miR-124. We transduced two HR-GSC with lentiviruses containing either
the control vector (V) or pre-miR-124. The generated stable lines (HR-GSC1.shNT/V
and HR-GSC1.shNT/ pre-miR-124; HR-GSC2.shNT/V and HR-GSC2.shNT/ pre-miR124) were selected in puromycin and the overexpression of miR-124 was confirmed by
taqman assays.
Loss of Function: Rest knock down cells have lower expression of REST and higher
expression of miR-124. We transduced two REST

knock down lines (HR-GSC

shREST) with lentiviruses containing either the control vector (V) or shmiR-124. The
generated double knock down (shREST and shmiR-124) stable lines (HRGSC1.shREST/V and HR-GSC1.shREST/ shmiR-124; HR-GSC2.shNT/V and HRGSC2.shNT/ pre-miR-124) are selected in puromycin and the knock down of miR-124
was confirmed by qRT-PCR.
We observed that upon gain or loss of function of miR-124 there is an increase and
decrease in the expression of miR-124 respectively.
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REST-miR-124 axis regulates cell proliferation, apoptosis and invasion in GSCs
in vitro
To understand the mechanism by which REST-miR-124 axis regulates the oncogenic
properties of GSCs we used the established LOF and GOF miR-124 cells and
performed tumorigenisis assays.
We performed a BrdU proliferation assay on the miR-124 GOF and LOF cells to
determine the proliferative capacity of these cells. We observed that upon over
expression of miR-124 (GOF) in two independent cells there is decrease in the cell
proliferation when compared to its controls as shown in fig (13 A) .Upon knock down of
miR-124 there is an increase in the percentage of BrdU incorporated cells indicating
these cells are dividing at a higher rate when compared to its controls Fig (13 B)
We also performed apoptosis assay, to determine the DNA fragmentation that results
from apoptosis. We observed that upon overexpression of miR-124 there is an increase
in the percentage of apoptotic cells when compared to its control.

Similarly upon

knocking down of miR-124 we observed that there is a decrease in the apoptosis (Fig
13 C & D)
To determine the role of miR-124 in invasion, we subjected the GOF of miR-124 cells
for invasion assay. Upon over expression of miR-124 we observed that there is a
decrease in the percentage of invading cells when compared to its controls. Next we
wanted to know if REST-miR-124 axis has any role in regulating invasion of GSCs. We
knock down miR-124 in REST knock down cells (shREST/shmiR-124) and performed
the invasion assay. We observed that there is an increase in the invasive potential of
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these double knock down cells (shREST/shmiR-124) when compared to its controls
(shREST/shmiRNT). (Fig 13 E & F)
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Figure 13: REST-miR-124 axis regulates cell proliferation, apoptosis and invasion
in GSCs in vitro. A & B: We performed a BrdU Proliferation assay on GOF and LOF
of miR-124 cells. We observed that upon over expression of miR-124 there is a
decrease in the percentage of proliferating cells.
C & D: Apoptotic assay was
performed on the LOF and GOF miR-124 cells. We observed that upon overexpression
of miR-124 there is an increase in the apoptotic cells. E &F: We performed an invasion
assay. Upon knocking down of miR-124 there is an increase in the percentage of
invading cells.

We have observed that over expression of miR-124 in the GSCs resulted in decreased
cell proliferation, increased apoptosis and decreased invasion. Upon knocking down of
miR-124 in the REST knock down cells lead to increased cell proliferation and invasion
and decreased apoptosis. From this we can conclude that REST-miR-124 axis
regulates the oncogenic properties of GSCs.

56

MiR-124 regulates survival of mice harboring GSC-derived brain tumors
REST-miR-124 axis regulates the oncogenic properties of GSCs in vitro. We wanted to
test if miR-124 has any role in regulating the tumorigenesis and affect the survival of
the tumor bearing mice. Two independent GOF of miR-124 (HR-GSC1.shNT/V and
HR-GSC1.shNT/ pre-miR-124; HR-GSC2.shNT/V and HR-GSC2.shNT/ pre-miR-124)
cell lines were generated and these are implanted into the brains of the nude mice and
Kaplan-Meier survival analyses is performed. Over expression of miR-124 in two
independent HR-GSC lines increased the survival of tumor bearing mice, indicating
miR-124 has tumor suppressor functions (fig 14).
B

A

p < 0.001

p<0.001

Figure 14: mir-124 regulates survival of the tumor bearing mice. Both the HRGSCs over expressing miR-124 when implanted into the brains of nude mice increased
the survival of tumor bearing mice.
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REST-miR-124 axis regulates survival of mice harboring GSC-derived brain
tumors
We observed that over expression of miR-124 increased survival of tumor bearing
mice. We wanted to know if REST-miR-124 axis has any role in the survival of mice. A
previous study has shown that REST knock down cells (shRest) when implanted into
the brain of nude mice have a longer survival than controls (shNT). We implanted the
double knock down cells (shREST/shmiR-124) and its control (shREST/shmiR-NT) into
the mice and performed the survival analysis. We observed that upon double knock
down (shREST/shmiR-124) down there is a decrease in the survival of tumor bearing
mice when compared to its control (fig 15). These results indicate that REST-miR-124
axis regulates the survival of mice harboring GSC derived tumors.

Figure 15: REST-mir-124 regulates survival of the tumor bearing mice. Upon
REST knock down the mice survived for longer. Double knock down of REST and miR124 decreased the survival of tumor bearing mice.
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REST-miR-124 axis regulates proliferation, apoptosis and invasion in GSCderived tumors in mouse brains
We observed that REST-miR-124 axis regulates proliferation, apoptosis and invasion in
vitro. We also found that REST-miR-124 axis regulates the survival of mice. We wanted
to determine if REST-miR-124 axis holds true in vivo. GSCs with either GOF or LOF of
miR-124 are implanted into the brain of nude mice. Mice were euthanized around 40
days of time and the brains were paraffin embedded and tumorigenic assays were
performed on the mouse brain tumor sections. To distinguish human cells from mouse
cells, the tumor sections are stained using anti-NuMa antibody that specifically stains
only human cells.
To measure the proliferative index in the tumor sections , the tumor sections are
double labelled with NuMa and Ki67( proliferative marker). Over expression of miR-124
led to decreased cell proliferation in the tumor sections. In the double knock down
tumor sections (shREST/shmiR-124) there is an increase in the proliferating cells when
compared to its control.(fig 16)
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B

Figure 16: Involvement of REST-miR-124 in cell proliferation. The tumor sections
are stained with human specific NuMa antibody (Green). Ki67 (red) a proliferative
marker stains the proliferating cells and Dapi (blue) stains all the cells of the tissue. A.
Over expression of miR-124 decreases the ki67 positive cells. B. Double knock down
of REST and miR-124 resulted in increase in cell proliferation. A quantitative
representation of the same is shown in a bar graph.

We performed TUNEL assay on the tumor sections. Upon over expression of miR-124
we observed that there is an increase in the percentage of apoptotic cells when
compared to controls. (Fig 17)

60

A

B
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Figure 17: REST-miR124 axis role in apoptosis in vivo. Tumor sections are
subjected to TUNEL labelling assay. Upon over expression of miR-124 there is an
increase in the number of TUNEL positive cells when compared to its controls (A).
Knock down of 124 in REST knock down cells decrease the number of apoptotic cells
(B).

Tumors formed by both HR-GSCs were found to be more invasive as we observed
tumor cells invading from the core of tumor to the pial surface of the brain. But upon
overexpression of miR-124, we observed there is decreased tumor invasion and
tumors formed are circumscribed (fig 18A). We wanted to check whether REST-miR61

124 axis has any role in GSC tumor invasion. Double knock down of REST and miR124 (shREST/shmiR-124) resulted in highly invasive tumors when compared to
controls (fig 18B). These results indicate that REST-miR-124 axis regulates cell
proliferation, apoptosis and invasion in GSC tumors.
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Figure18: Decreased cell invasion caused by shRest is reversed by knockdown
of miR-124 in mouse tumors. Upon over expression of miR-124 there is a decrease
in the invasion which is shown by staining the human cells implanted in the mouse
brain with NuMa. Knock down of miR-124 led to the formation of more invasive tumors.
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Summary
In this section we investigated the mechanism by

which the REST-miR-124 axis

regulates the oncogenic properties of GSCs. We observed that upon over expression
of miR-124 there is a decrease in the proliferation of the cells, increased apoptosis and
decreased invasion in vitro. Implantation of the GSCs with GOF of miR-124 in the
brains of nude mice led to increased survival of the tumor bearing mice. Knock down of
miR-124 in REST knock down cells (double knock downs) led to decreased survival of
the tumor bearing mice indicating miR-124, is a tumor suppressor gene. In vivo
tumorigenic assays were performed on the brain sections, we observed increase in the
number of proliferative (ki67 positive) cells and invading cells

and decrease in

apoptotic cells in the mice implanted with double knock down cells (shRest/shmiR-124).
Our finding concludes that miR-124, is a target of REST and they act as an axis that
regulates the oncogenic properties of GSCs.
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Chapter 6. REST-miR-203 axis regulates invasion but not proliferation or
apoptosis of GSCs
Rationale
Genome wide analyses have identified two microRNAs miR-124 and miR-203 that
might play a role in regulating GSC tumorigenesis. In chapter 3, we established that a
reciprocal relationship exists between REST (protein) expression and miR-124/203
expression. Further, REST binding to the RE1 sites upstream of TSS was confirmed
by ChIP and luciferase assays. Additionally, In chapter 4 we have identified that REST
regulates miR-124 and there by regulates cell proliferation, apoptosis and invasive
potential of the GSCs both in vitro and in vivo. In the current chapter we investigated
the role of the REST-miR-203 axis in regulating oncogenic properties of GSCs. miR203 has been identified as a skin-specific microRNA and promotes epidermal
differentiation by inducing cell cycle exit. Expression of miR-203 has been found to be
dysregulated in diseases like psoriasis, rheumatoid arthritis and cancers. Studies have
shown that miR-203 is expressed at lower levels in glioma tissue when compared to
the normal brain. Studies have shown that miR-203 regulates cell proliferation, invasion
and apoptosis of established glioma cell lines U251. The current study mainly focuses
on the mechanism by which REST-miR-203 axis regulates the oncogenic properties of
GSCs. Either LOF or GOF of miR-203 cells were generated using lentiviruses as
described in chapter 1. After confirming the expression levels of miR-203 the cells are
subjected to in vitro tumorigenic assays (proliferation, apoptosis and invasion). Further
the LOF and GOF cells are implanted in the nude mice and survival of the tumor
bearing mice is analyzed. The tumor sections were evaluated for proliferation,
apoptosis and invasive potential.
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REST-miR-203 axis regulates invasion, but not cell proliferation and apoptosis, in
GSCs in vitro
To determine the roles of miR-203 in REST-mediated tumorigenicity, we first
determined whether its manipulation in GSCs affected cell proliferation and apoptosis
in vitro. We first used the miR-203 gain-of-function cells (HR-GSC1.shNT/V and HRGSC1.shNT/ pre-miR-203 HR-GSC2.shNT/V and HR-GSC2.shNT/ pre-miR-203) and
subjected them to bromodeoxyuridine (BrdU)-labeling assay as shown in Figure 19 .We
observed that over expression of miR-203 in two independent GSCs did not affect the
cell proliferation. To determine the apoptotic status of these cells, we performed an
apoptosis assay and found that over expression of miR-203 did not alter the apoptosis
in these cells (Figure 19).
We then determined whether the REST-miR-203 axis impacted cell proliferation or
apoptosis.

We found earlier REST knock down cells (shREST) cells showed

decreased proliferation rates and higher apoptosis when compared to the control cells
(shNT). We wanted to determine if knock down of miR-203 in REST knock down cells
(double knockdown shRESTshmiR-203) has any impact on cell proliferation or
apoptosis.miR-203 had no effect on shREST mediated cell proliferation and apoptosis
in both the HR-GSCs in vitro as shown in figure 19 (A-D).
To determine the role of miR-203 in invasion in vitro, we took the miR-203 lossand gain-of-function cell lines described in the preceding paragraph and determined the
impact of these manipulations on cellular invasion using invasion chamber assays.
The addition of exogenous miR-203 in either HR-GSC1 or HR-GSC2 cells decreased
invasion when compared with the control vector, indicating that miR-203 negatively
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regulates the invasion as shown in figure 19 .To determine whether the REST-miR203 axis regulates cellular invasion, we subjected both the HR-GSC1 and HR-GSC2
cell types to shRest/shmiR-203 double knockdown.

Results showed that the

decreased cellular invasion caused by shRest could be reversed by the addition of
shmiR-203 as shown in Fig 19. Thus, the REST-miR-203 axis controls cellular invasion
in GSCs in vitro. (Fig 19 E &F)
A

B

C
D
F
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Figure 19: REST-miR-203 axis regulates invasion but not cell proliferation or
apoptosis in GSCs. miR-203 gain-of-function cells HR-GSC1.shNT/ pre-miR-203 and
HR-GSC2.shNT/ pre-miR-203 were subjected to in vitro BrdU-labeling assays to
determine their cell proliferation properties (A) and TUNEL-labeling assays to
determine their apoptotic status (B) compared with their corresponding HRGSC1.shNT/V and HR-GSC2.shNT/V controls. As shown, none of the miR-203
manipulations made a significant difference either in their cell proliferation or apoptotic
properties in either of the two HR-GSC lines. Previous studies indicated that the
expression of shRest in both HR-GSC1 and HR-GSC2 cells results in decreased cell
proliferation and increased apoptosis as compared with shNT-expressing cells (17).
Additional loss-of-function manipulations with shmiR-203 in these cells (resulting in
double knockdown shRest/shmiR-203) did not significantly alter either cell proliferation
(C) or apoptosis (D). In contrast, when the same cells were subjected to invasion
chamber assays, gain of function of miR-203 in both HR-GSC1 and HR-GSC2 cells
decreased invasion when compared with the control vector (E). Similarly, when double
knockdown of shRest/shmiR-203 was performed in HR-GSC1 and HR-GSC2 cells, the
decreased cellular invasion caused by shRest was reversed by the addition of shmiR203 (F).
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MiR-203 regulates survival of mice harboring GSC-derived brain tumors
To determine whether miR-203 is relevant in the regulation of tumorigenesis, we
determined whether its manipulation in GSCs affected the survival of mice bearing
brain tumors derived from the altered GSCs. We performed miR gain-of-function
experiments, in which we took the two HR-GSC control lines transduced with shNT that
we characterized previously. Both lines express high REST and low miR-203. We
transduced both these lines with lentiviruses containing either the vector (V) control or
premiR-203, selected cells expressing the virus-encoded drug resistance, and
confirmed the overexpression of miR-203 by taqman assays in the stable cell lines
(HR-GSC1.shNT/V and HR-GSC1.shNT/ pre-miR-203; HR-GSC2.shNT/V and HRGSC2.shNT/ pre-miR-203). We then transplanted these cells into the brains of nude
mice using a screw-guided system we had utilized before and performed Kaplan Meier
survival analyses. Overexpression of miR-203 in either of the independent HR-GSC
lines increased the survival of tumor-bearing mice, indicating that miR-203 has a tumorsuppressor function in GSCs (Fig 20).
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Figure 20: MiR-203 regulates survival of mice harboring brain tumors derived
from both HR-GSC1 and HR-GSC2 cells. Kaplan-Meier survival plots of mice
harboring (A) HR- HR-GSC1.shNT/V and HR-GSC1.shNT/pre-miR-203 and (B) HRGSC2.shNT/V and HR-GSC2.shNT/ pre-miR-203 cells show that overexpression of
miR-203 in either HR-GSC1 or HR-GSC2 cells increased the survival of tumor-bearing
mice, indicating that miR-203 has a tumor-suppressor function in GSCs.
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REST-miR-203 axis regulates survival of mice harboring GSC-derived brain
tumors
We then determined whether the tumor suppressor function of miR-203 is
mechanistically connected to REST. We took the two previously studied HR-GSC
stable lines that were transduced with shRest: HR-GSC1/shRest and HR-GSC2/shRest
(expressing low REST and high miR-203) .As described before, REST knockdown with
shRest in these cells causes longer survival in tumor-bearing mice.

To determine

whether miR-203 can rescue these effects of shRest in GSCs, we performed
shRest/shmiR-203 double knockdown in these cells. We transduced each of the GSC
lines with lentiviruses containing shNT control, shRest, shRest/shNT, or shRest/shmiR203; selected cells expressing the virus-encoded drug resistance; and confirmed the
knockdown of miR-203 by taqman assays followed by qRT-PCR analyses. We then
transplanted these cells into the brains of nude mice as described in the preceding
paragraph and performed Kaplan Meier survival analyses. The mouse survival was
longer in the shRest-expressing HR-GSC1 cells than in the shNT controls, as
expected. Also, as expected, expression of additional shNT in the shRest-expressing
cells (shRest/shNT: as a control for the expression of shmiRs) did not alter survival
significantly. However, the double knockdown of shRest/shmiR-203 attenuated the
increase in survival caused by shRest in these cells.

The double knockdown of

shRest/shmiR-203 caused decreased survival when compared to the control
shRest/shNT cells. These results indicated that the REST-miR-203 axis regulates the
tumorigenesis of GSCs.
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Figure 21: REST-miR-203 axis regulates survival of mice harboring tumors derived from
both HR-GSC1 and HR-GSC2 cells. Kaplan-Meier survival plots of mice harboring (A)
HR-GSC1.shNT, HR-GSC1.shRest, HR-GSC1.shRest/shNT and HR
GSC1.shRest/shmiR-203 and (B) HR-GSC2.shRest, HR-GSC2.shRest/shNT and HRGSC2.shRest/shmiR-203. Knockdown of REST by shRest in HR-GSC1 and HR-GSC2
cells caused increased survival when compared with their shNT controls, as
expected27. Additional expression of shNT in these shRest-expressing cells did not
significantly alter survival. In contrast, the double-knockdown shRest/shmiR-203 cells
reversed the increased survival caused by single shRest in both.
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REST-miR-203 axis regulates invasion, but not cell proliferation and apoptosis, in
GSC-derived tumors in mouse brains
As described above, we found the REST-miR-203 axis regulates survival in mice
harboring GSC tumors. To determine whether the properties of the REST-miR-203
axis seen in in vitro assays were also present in mouse brain tumors, we took the
GSCs with miR-203 and REST manipulations described in the preceding sections,
transplanted them into the brains of nude mice, waited for 40 days, euthanized all the
mice, and examined their brain sections using immunofluorescence analysis.

To

differentiate the human GSC cells from the mouse brain cells, we stained the tumor
sections with anti-NuMA antibody that selectively stains human cells. Double labeling
of NuMA and the proliferation marker Ki67 showed that overexpression of miR-203 in
the HR-GSC tumors or knockdown of miR-203 in the HR-GSC/shRest tumors did not
significantly alter tumor cell proliferation. (Fig 22)
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Figure 22: REST-miR-203 axis does not regulate proliferation in GSC –derived tumors in
mouse brain. HR-GSC1 and HR-GSC2 cells with various REST and miR-203 manipulations
described were transplanted into mouse brains. All mice were euthanized at day 40, and
mouse brain sections were labeled with antibodies against NuMA (to detect human cells
present among the mouse brain cells) and Ki67 (to detect cell proliferation).Brain sections were
then examined using immunofluorescence analysis. Double labeling of brain sections with
NuMA and Ki67 showed that overexpression of miR-203 in either of the HR-GSC tumors (A &
B) or double knockdown of miR-203 in either the HR-GSC1/shRest or HR-GSC2/shRest
tumors (C & D) did not significantly alter tumor cell proliferation.

TUNEL assays also showed that neither the overexpression of miR-203 in the
two HR-GSC tumors nor the knockdown of miR-203 in the two HR-GSC/shRest tumors
significantly affected apoptosis. (Fig 23)
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Figure 23: REST-miR-203 axis does not regulate apoptosis in GSC –derived tumors in
mouse brains. TUNEL assay was performed on the mice brain sections. Either over
expression of miR-203 in the two HR-GSC tumors (A & B) or knockdown of miR-203 in
the HR-GSC/shREST tumors( C & D) did not show any significant alteration in
apoptosis.
In contrast, HR-GSC1 and HR-GSC2 tumors, in which the cells were found to
show a very high degree of migration causing cell invasion from the core of the tumor
to the pial surface, were suppressed by overexpression of miR-203, which resulted in
decreased cellular migration and distinct circumscribed tumors as shown in figure 24.
The role of the REST-miR-203 axis in blocking tumor invasiveness was further
illustrated when the decreased tumor invasion caused by knockdown of REST was
reversed by the additional knockdown of miR-203, which resulted in a highly invasive
phenotype in both HR-GSC1 and HR-GSC2 tumors as shown in figure. Thus, these
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results indicated that the REST-miR-203 axis regulates invasion but not cell
proliferation or apoptosis in GSC tumors. (Fig 24)
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Figure 24: REST-miR-203 axis regulates the invasion in GSC-derived tumors in mouse
brains. Overexpression of miR-203 in either of the HR-GSC tumors (A & B)) resulted in the
blockade of invasion and the formation of circumscribed tumors. Similarly, the decreased
invasion seen in either of the HR-GSC tumors expressing shRest was reversed in
shRest/shmiR-203 double-knockdown tumors (C & D).
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Chapter 7: Discussion
Glioblastoma is the most common malignant adult brain tumor with an average life
expectancy of 9-12 months (4, 22). Despite decades of basic science and clinical
research, there is no widely used prognostic criterion for GBM patients. The
mechanisms that initiate different tumors still remains unknown, however several
evidences point towards role of impaired stem cell development in tumor initiation.
GBM tumors are believed to be caused by self-renewing, glioblastoma-derived stemlike cells (GSCs). These GSCs are resistant to chemo- and radiation therapies, and are
believed to be responsible for tumor recurrence (1, 27, 84, 85). REST, a transcriptional
repressor of neuronal differentiation and a known regulator of self-renewal in neural
stem cells, has been recently identified in our laboratory and others to regulate
tumorigenesis in GSCs. However, understanding the mechanism by which REST
regulates oncogenic properties of GSCs is critical to developing therapeutic
approaches. Here we report the potential mechanisms by which REST regulates
oncogenic properties of GSCs.
Recent evidences suggest that microRNA can be therapeutic targets for various
cancers(63). To understand the candidate miRNAs regulated by REST we altered
REST levels in GSCs and performed microRNA microarray. Our miRNA profiling
identified two tumor suppressor miRNAs miR-124 and miR-203. Studies have shown
that both these microRNAs are expressed at lower levels in the glioma tumors when
compared to the surrounding normal tissue. We also observed a negative correlation
between the expression levels of REST and both these microRNAs in the cancer
genome atlas (TCGA) datasets of GBM patients. Our results indicated that upon REST
knock down both the microRNAs are up regulated and vice versa. REST binding to the
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gene chromatin of miR-124/203 was confirmed by chromatin immunoprecipitation
(ChIP) and luciferase assays. In the current study role of REST and miR-124 an/miR203 axis was studied independently.
Here, we show that REST-miR-124 axis regulates the cell proliferation, apoptosis and
invasion in HR-GSC tumors. Over expression of miR-124 led to increased survival in
tumor bearing mice and the tumors formed are more circumscribed. We are the first
ones to show that REST-miR-124 axis regulates the oncogenic properties in GSCs
derived from the patient tumors. Studies have shown that miR-124 is the most
abundant microRNA in adult and embryonic central nervous system (CNS)(42, 70, 82).
Studies have also shown that down regulation of miR-124 is correlated with poor
survival in GBM patients (67, 86). Previous studies have shown that overexpression of
miR-124, induced differentiation in neural stem cells, mouse ES cells and mouse
embryonal carcinoma cells. miR-124 also promoted cell cycle arrest in established
GBM cells that are deprived of growth factors. Growth factor signaling (EGF, FGF, and
PDGF) and epigenetic modification of the transcriptional regulatory sequences of the
genes that encode miR-124 are the two possible mechanisms that it is suppressed in
GBM tumors(70, 82). Previous studies indicated that the ability of miR-124 to induce
differentiation depends on the cell type, developmental timing and other factors.
Abrogation of the growth factor signaling along with the overexpression of miR-124
might enhance the cell cycle arrest and differentiation of cells. Studies have shown that
miR-124 targets cell cycle regulators like CDK6 and its downstream targets like
phosphorylated retinoblastoma (RB) (87) . Targeted delivery of miR-124 to the tumor
cells may be therapeutically valuable for GBM disease treatment. Targeted in vivo
delivery faces many challenges including the limited stability of miRNA, rapid blood
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clearance, off target effects and poor cellular uptake. Stable and chemically modified
nucleotides ( locked nucleic acids, 2`-O-methylation) can be made for delivery which
can be delivered at the site and also can be used to augment the specific binding of
miRNA to the miRISC complex.(88). miRNAs can also be delivered as a precursor by
a plasmid through viral vectors. As both mir-124 and miR-203 are suppressed in tumor
tissue when compared to the surrounding brain tissue we need to overexpress both
these microRNAs. Lower expression levels of the microRNAs should be supplemented
with oligonucleotide mimics containing the same sequence as endogenous miRNA,
known as microRNA mimics. These mimics should have an ability to enter the RISC
complex and affect miRNA target mRNAs. Double stranded mimics composed of
passenger strand (complementary sequence to mature miRNA) and guide strand
(sequence identical to mature miRNA) should be used for delivery as they have a
higher efficiency when compared to single stranded RNA. Synthetic conjugates such as
cholesterol can be used for the delivery of mimics (89). Currently, there are several lipid
–based delivery systems available for targeted delivery such as polycationic liposomehyaluronic acid (LPH) nanoparticles. In addition to synthetic polymer materials,
naturally occurring polymers such as chitosan, protamine and atellocollagen and
peptides derived from protein translocation domains can be used for delivery. The
application of natural compounds is limited by immunogenicity. Atellocollagen exhibits
least immunogenic response when compared to other natural polymers. Studies have
shown that miR-34a/atellocollagen complex when delivered intratumorally in lung
cancers suppressed tumor growth (90) .
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Our results indicated that REST-miR-203 axis regulates only invasion of GSCs both in
vitro and in vivo but not cell proliferation and apoptosis. The tumors formed by the
knockdown of miR-203 are highly invasive when compared to their controls and the
mice die much faster. One of the principal reasons of our failure to provide better
therapeutic approaches for GBM patients is due to the invasive nature of these tumors.
Previously, it was found that REST regulates invasion of HR-GSCs (17, 18). However,
the mechanism of this process was unclear. Here, we show that a novel REST-miR203 axis regulates invasion in HR-GSC tumors, with REST suppressing miR-203 gene
expression and miR-203 functioning as a tumor suppressor. Earlier ChIP-Seq assays
using a mouse kidney cell line had indeed found miR-203 to be a potential target of
REST in those cells (91). The finding that REST also represses miR-203 in HR-GSCs
indicates that this regulatory axis likely operates in many different cell types. Recent
observation that miR-203 expression was significantly lower in a large number of highgrade GBM tumor tissues than in low-grade glioma tissues or normal brain tissues (92,
93), would support miR-203’s role as a tumor suppressor in GBM. In addition, miR-203
is also known to act as a tumor suppressor in other cancers (94) .
Interestingly, the publications on GBM cited above also indicated that miR-203
positively regulated invasion as well as cell proliferation in some glioma cell lines (92,
93) . However, our studies indicate that the REST-miR-203 axis specifically regulates
invasion but not cell proliferation or apoptosis in HR-GSCs. It is unclear whether this
difference in activity is due to the use of GSCs derived from primary GBM tumors in the
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current study rather than the glioma lines used in the other studies, as cell culture
conditions that can affect various signaling pathways (41), or a special property of the
HR class of GSCs.

Recent studies have discovered a six-miR gene signature, which includes miR-203, in
the serum of colorectal cancer patients that can be used as a biomarker and prognostic
indicator (95). While two of the miR levels were elevated in colorectal cancer patient
serums, levels of the other four, including miR-203, were lowered. Although lowered
miR-203 levels were also seen in the HR-GSCs in our study, it is unknown whether
such a miR signature exists in GBM. This needs to be addressed in future studies. Our
study does suggest, however, that because GBM patients can now potentially be
stratified based on the REST gene signature (28), the REST-miR-203 mechanism
could potentially be manipulated in therapeutic approaches to block GBM invasion.
The downstream effector molecules of the REST-miR-124/miR-203 axis are still
unknown. There are many known targets of miR-124/miR-203 but whether any of them
are relevant in the context of HR-GSCs is unclear. To identify relevant targets, we
performed a genome-wide mRNA expression analysis of HR-GSC1 and HR-GSC2
cells expressing either shNT or shREST (Stable lines). Using prediction programs we
predicted the target genes of for microRNAs. We first filtered the genes whose
expression was down regulated when REST was knocked down with a fold change of
2 or more and selected only those genes that contained potential miR-124 or miR-203
binding site(s) in their 3’ untranslated region. Sorting for the potential targets that were
common to both HR-GSC lines resulted in a short list of 25 and 18 genes for REST84

miR-124 and REST-miR-203 respectively. Ingenuity pathway analysis (IPA) of the
potential target genes of the REST-miR-124 indicated that these genes are involved in
metabolism of amino acids, lipids and nucleic acids. Similarly, upon analysis of the
REST-miR-203 axis target genes, the top gene ontology was found to be involved in
cellular movement. A network map of these genes obtained by performing an Ingenuity
Pathway Analysis indicates a large network composed of two major hubs: one
composed of genes involved in inflammation, angiogenesis, cell growth and apoptosis;
the other composed of genes involved in ubiquitin and GTP binding proteins.

A

canonical pathway analysis of the 18 genes indicated that they are involved in various
signaling, such as axonal signaling, ERK5 and p53 signaling, growth hormone signaling
and melanocyte development. Efforts are under way in our laboratory to validate the
actual targets of the REST-miR-124/203 axis using mouse orthotopic tumor models.
Conclusion/Summary: The REST-miR-124 axis regulates cell proliferation, apoptosis
and invasion of the GSCs both invitro and in vivo. The REST-miR-203 axis specifically
regulates the invasion potential of glioblastoma stem cells but not cell proliferation or
apoptosis both in vitro and in vivo. Since invasion is a major hallmark of high REST
GSC tumors and the REST-miR-203 axis could be potentially targeted to block the
invasion.
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